Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated:  12/31/1969
Wayne State University- Integrative Bioscience Center
mi
from 98109
Detroit, MI
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated: 12/31/1969
Wayne State University- Integrative Bioscience Center
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
2485
mi
from 98109
Boston, MA
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated:  12/31/1969
Be Well Medical Center
1922
mi
from 98109
Berkley, MI
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated: 12/31/1969
Be Well Medical Center
1922
mi
from 98109
Berkley, MI
Click here to add this to my saved trials
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
2405
mi
from 98109
Bronx, NY
Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
2405
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
University of Southern California
962
mi
from 98109
Los Angeles, CA
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
University of Southern California
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
960
mi
from 98109
Los Angeles, CA
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
960
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Harbor General/UCLA
976
mi
from 98109
Torrance, CA
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Harbor General/UCLA
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Center - Denver
1022
mi
from 98109
Denver, CO
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Center - Denver
1022
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Univ. of Hawaii at Manoa, Leahi Hosp.
2679
mi
from 98109
Honolulu, HI
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Univ. of Hawaii at Manoa, Leahi Hosp.
2679
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Rush-Presbyterian/St. Lukes (Chicago)
mi
from 98109
Chicago, IL
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Rush-Presbyterian/St. Lukes (Chicago)
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Cook County Hosp. CORE Ctr.
1730
mi
from 98109
Chicago, IL
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Cook County Hosp. CORE Ctr.
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
1716
mi
from 98109
Saint Louis, MO
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
1716
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
HIV Prevention & Treatment CRS
mi
from 98109
HVTN 722 West 168th Street MSPH Bldg., NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
HIV Prevention & Treatment CRS
mi
from 98109
HVTN 722 West 168th Street MSPH Bldg., NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
2402
mi
from 98109
New York, NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Cornell CRS
2401
mi
from 98109
New York, NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Cornell CRS
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
NY Univ. HIV/AIDS CRS
2402
mi
from 98109
New York, NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
NY Univ. HIV/AIDS CRS
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Community Health Network Inc
2154
mi
from 98109
Rochester, NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Community Health Network Inc
2154
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Univ. of Rochester ACTG CRS
2154
mi
from 98109
Rochester, NY
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Univ. of Rochester ACTG CRS
2154
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
2337
mi
from 98109
Chapel Hill, NC
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Wake County Health and Human Services Clinical Research Site
mi
from 98109
Chapel Hill, NC
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Wake County Health and Human Services Clinical Research Site
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
1967
mi
from 98109
Cincinnati, OH
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS
2006
mi
from 98109
Columbus, OH
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
2371
mi
from 98109
Philadelphia, PA
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Stanley Street Treatment and Resource
mi
from 98109
Providence, RI
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Stanley Street Treatment and Resource
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
The Miriam Hosp. ACTG CRS
2486
mi
from 98109
Providence, RI
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
The Miriam Hosp. ACTG CRS
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics CRS
1971
mi
from 98109
Nashville, TN
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics CRS
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
1682
mi
from 98109
Dallas, TX
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Texas Galveston
1937
mi
from 98109
Galveston, TX
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Texas Galveston
1937
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated:  12/31/1969
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
mi
from 98109
Manguinhos,
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial
Status: Enrolling
Updated: 12/31/1969
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
mi
from 98109
Manguinhos,
Click here to add this to my saved trials
A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine
RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905.
Status: Enrolling
Updated:  12/31/1969
Vaccine Clinical Research Center
mi
from 98109
Rockville, MD
A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine
RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905.
Status: Enrolling
Updated: 12/31/1969
Vaccine Clinical Research Center
mi
from 98109
Rockville, MD
Click here to add this to my saved trials
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs (701)
1065
mi
from 98109
San Diego, CA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs (701)
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
975
mi
from 98109
Torrance, CA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
975
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS (901)
2732
mi
from 98109
Miami, FL
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
2732
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS
2178
mi
from 98109
Atlanta, GA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
1733
mi
from 98109
Chicago, IL
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Indiana University Hospital (2601)
1868
mi
from 98109
Indianapolis, IN
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Indiana University Hospital (2601)
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
IHV Baltimore Treatment CRS (4651)
2328
mi
from 98109
Baltimore, MD
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
IHV Baltimore Treatment CRS (4651)
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
2485
mi
from 98109
Boston, MA
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
1721
mi
from 98109
Saint Louis, MO
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
1721
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
Beth Israel Med Ctr
2402
mi
from 98109
New York, NY
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
Beth Israel Med Ctr
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated:  12/31/1969
HIV Prevention & Treatment CRS (30329)
2401
mi
from 98109
New York, NY
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Status: Enrolling
Updated: 12/31/1969
HIV Prevention & Treatment CRS (30329)
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials